Feb 08, 2022 / 01:00PM GMT
Operator
Welcome to the Amgen Business Review broadcast from the Amgen campus in Thousand Oaks, California.
Robert A. Bradway - Amgen Inc. - Chairman, CEO & President
Hello, everyone, and thank you for joining us. We'll be talking to you mostly today about the future of our business, and in particular, what we expect to deliver through 2030. As we think about what's next, we're encouraged by our past accomplishments and we're ready and looking forward to delivering on the future for patients and shareholders.
As the industry's response to the pandemic has shown, this is an extraordinary time for biotechnology. Science and technology are converging in ways that are accelerating the cadence of innovation in our field. And though our industry is not without its challenges, we believe the fundamentals remain very attractive for global companies that are able to innovate at speed, and we expect to be 1 of those companies. We've been a leader in biotechnology for the past 40 years, and we think we're well positioned to maintain that leadership for decades to come.
Amgen Inc Business Review Meeting Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot